School of Pharmacy and Medical Science, Menzies Health Institute of Queensland, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia.
School of Pharmacy and Medical Science, Menzies Health Institute of Queensland, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia; Australian Botanical Bioscience Pty. Ltd., Australia.
Biomed Pharmacother. 2021 Aug;140:111790. doi: 10.1016/j.biopha.2021.111790. Epub 2021 Jun 11.
The antitumor activity of the tea tree oil (TTO) derived product, Melaleuca Alternifolia Concentrate (MAC) was characterized mechanistically at the molecular and cellular level. MAC was analyzed for its anticancer activity against human prostate (LNCaP) and breast (MCF-7) cancer cell lines growing in vitro. MAC (0.02-0.06% v/v) dose-dependently induced the intrinsic (mitochondrial) apoptotic pathway in both the LNCaP and MCF-7 cell lines, involving increased mitochondrial superoxide production, loss of mitochondrial membrane potential (MMP), caspase 3/7 activation, as well as the presence of TUNEL and cleaved-PARP cell populations. At concentrations of 0.01-0.04% v/v, MAC caused cell cycle arrest in the G-phase, as well as autophagy. The in vivo anticancer actions of MAC were examined as a treatment in the FVB/N c-Neu murine model for spontaneously arising breast cancers. Intratumoral MAC injections (1-4% v/v) significantly suppressed tumor progression in a dose-dependent manner and was associated with greater levels of tumor infiltrating neutrophils exhibiting anticancer cytotoxic activity. Induction of breast cancer cell death by MAC via the mitochondrial apoptotic pathway was also replicated occurring in tumors treated in vivo. In conclusion, our data highlights the potential for the Melaleuca-derived MAC product inducing anticancer neutrophil influx, supporting its application as a novel therapeutic agent.
茶树油(TTO)衍生产品——互叶白千层浓缩物(MAC)的抗肿瘤活性在分子和细胞水平上得到了机制特征化。分析了 MAC 对体外生长的人前列腺(LNCaP)和乳腺癌(MCF-7)癌细胞系的抗癌活性。MAC(0.02-0.06%v/v)浓度依赖性地诱导 LNCaP 和 MCF-7 细胞系中的内在(线粒体)凋亡途径,涉及增加线粒体超氧化物产生、线粒体膜电位(MMP)丧失、半胱天冬酶 3/7 激活以及 TUNEL 和裂解-PARP 细胞群体的存在。在 0.01-0.04%v/v 的浓度下,MAC 导致细胞周期在 G 期停滞,并发生自噬。MAC 的体内抗癌作用在 FVB/N c-Neu 自发发生乳腺癌的小鼠模型中作为治疗进行了检查。肿瘤内 MAC 注射(1-4%v/v)以剂量依赖性方式显著抑制肿瘤进展,并与表现出抗癌细胞毒性活性的浸润肿瘤中性粒细胞水平更高相关。通过线粒体凋亡途径诱导乳腺癌细胞死亡的 MAC 也在体内治疗的肿瘤中得到复制。总之,我们的数据强调了 Melaleuca 衍生的 MAC 产品通过诱导抗癌中性粒细胞浸润来发挥抗癌作用的潜力,支持其作为一种新型治疗剂的应用。